LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

LLY

877.96

-2.32%↓

JNJ

240.27

+0.43%↑

ABBV

209.68

-0.75%↓

NVS

148.25

-0.86%↓

MRK

119.68

+0.62%↑

Search

Pfizer

Chiusa

SettoreSettore sanitario

27.06 -1.64

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

27.02

Massimo

27.52

Metriche Chiave

By Trading Economics

Entrata

-5.2B

-1.6B

Vendite

903M

18B

P/E

Media del settore

19.684

57.05

EPS

0.66

Rendimento da dividendi

6.38

Margine di Profitto

-9.387

Dipendenti

75,000

EBITDA

-4.9B

756M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+5.44% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

6.38%

2.52%

Utili prossimi

5 mag 2026

Prossima data del Dividendo

12 giu 2026

Prossima data del' Ex Dividendo

8 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

696M

152B

Apertura precedente

28.7

Chiusura precedente

27.06

Notizie sul Sentiment di mercato

By Acuity

49%

51%

156 / 349 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Pfizer Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 feb 2026, 12:25 UTC

Utili

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

20 gen 2026, 10:40 UTC

Acquisizioni, Fusioni, Takeovers

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update

20 gen 2026, 07:47 UTC

Acquisizioni, Fusioni, Takeovers

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

11 mar 2026, 11:02 UTC

Discorsi di Mercato

Sanofi, Regeneron's Eczema Drug Might Face Competition From Pfizer -- Market Talk

10 mar 2026, 12:50 UTC

Utili

BioNTech Stock Plunges 17% After Earnings. Why the Drugmaker Faces a Perfect Storm. -- Barrons.com

10 mar 2026, 11:18 UTC

Utili

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock. -- Barrons.com

9 mar 2026, 09:43 UTC

Azioni calde

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

10 feb 2026, 21:51 UTC

Utili

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10 feb 2026, 21:17 UTC

Utili

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

3 feb 2026, 21:36 UTC

Utili

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3 feb 2026, 19:56 UTC

Utili

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb 2026, 19:46 UTC

Utili

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3 feb 2026, 17:35 UTC

Utili

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb 2026, 17:30 UTC

Utili

These Stocks Are Today's Movers: Palantir, PayPal, Novo Nordisk, Pfizer, Merck, AMD, Gartner, and More -- Barrons.com

3 feb 2026, 13:50 UTC

Utili

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb 2026, 13:06 UTC

Utili

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb 2026, 12:45 UTC

Utili

These Stocks Are Today's Movers: Palantir, PayPal, Teradyne, Tesla, Pfizer, AMD, Merck, and More -- Barrons.com

3 feb 2026, 12:02 UTC

Utili

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3 feb 2026, 11:48 UTC

Utili

Pfizer: About 20 Key Pivotal Study Starts Planned for 2026 >PFE

3 feb 2026, 11:48 UTC

Utili

Pfizer: Enters 2026 With Clear Strategic Priorities, Growing Late-Stage Pipeline >PFE

3 feb 2026, 11:47 UTC

Utili

Pfizer: Current Financial Guidance Doesn't Anticipate Any Stock Buybacks in 2026 >PFE

3 feb 2026, 11:46 UTC

Utili

Pfizer Sees 2026 Adjusted R&D Expenses $10.5B-$11.5B >PFE

3 feb 2026, 11:45 UTC

Utili

Pfizer Reaffirms 2026 Guidance >PFE

3 feb 2026, 11:45 UTC

Utili

Pfizer 4Q Rev $17.56B >PFE

3 feb 2026, 11:45 UTC

Utili

Pfizer Sees FY Adj EPS $2.80-Adj EPS $3.00 >PFE

3 feb 2026, 11:45 UTC

Utili

Pfizer 4Q Adj EPS 66c >PFE

3 feb 2026, 11:45 UTC

Utili

Pfizer 4Q Loss/Shr 29c >PFE

3 feb 2026, 11:45 UTC

Utili

Pfizer 4Q Loss $1.65B >PFE

3 feb 2026, 11:45 UTC

Utili

Pfizer Sees FY Rev $59.5B-$62.5B >PFE

3 feb 2026, 10:41 UTC

Utili

These Stocks Are Today's Movers: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, DaVita, and More -- Barrons.com

Confronto tra pari

Modifica del prezzo

Pfizer Previsione

Obiettivo di Prezzo

By TipRanks

5.44% in crescita

Previsioni per 12 mesi

Media 29.07 USD  5.44%

Alto 36 USD

Basso 25 USD

Basato su 22 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Pfizer - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

22 ratings

8

Acquista

12

Mantieni

2

Vendi

Punteggio Tecnico

By Trading Central

22.855 / 23.85Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

156 / 349 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat